✦ LIBER ✦

Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma

✍ Scribed by Marek Hus; Norbert Grzasko; Marta Szostek; Andrzej Pluta; Grzegorz Helbig; Dariusz Woszczyk; Maria Adamczyk-Cioch; Dariusz Jawniak; Wojciech Legiec; Marta Morawska; Justyna Kozinska; Piotr Waciński; Anna Dmoszynska

Publisher: Springer
Year: 2011
Tongue: English
Weight: 218 KB
Volume: 90
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-011-1276-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Thalidomide, dexamethasone, Doxil and Ve

Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed–refractory multiple myeloma

✍ Massimo Offidani; Laura Corvatta; Claudia Polloni; Silvia Gentili; Anna Mele; Ri 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 293 KB

High-dose melphalan is an effective salv

High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantation

✍ Gesine Bug; Johannes Atta; Stefan A. Klein; Bernd Hertenstein; Lothar Bergmann; 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 107 KB

A staged approach with vincristine, adri

A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma

✍ C. S. Chim; A. K. W. Lie; E. Y. T. Chan; Y. Y. Leung; S. C. W. Cheung; S. Y. T. 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 319 KB

Early versus delayed autologous transpla

Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma

✍ Shaji K. Kumar; Martha Q. Lacy; Angela Dispenzieri; Francis K. Buadi; Suzanne R. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 967 KB

Clinical efficacy of a bortezomib, cyclo

Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study

✍ Yeo-Kyeoung Kim; Sang-Kyun Sohn; Jae-Hoon Lee; Deok-Hwan Yang; Joon-Ho Moon; Jae 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 175 KB

Sequential vincristine, adriamycin, dexa

Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial

✍ Hye Jin Kim; Sung-Soo Yoon; Dong Soon Lee; Sang Kyun Sohn; Hyeon Seok Eom; Jung 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 184 KB